79-88-9 Usage
Uses
Used in Pharmaceutical Industry:
4-nitro-N-phenyltoluene-2-sulphonamide is used as an intermediate in the synthesis of various pharmaceuticals due to its versatile chemical properties.
Used in Dye Industry:
4-nitro-N-phenyltoluene-2-sulphonamide is used as an intermediate in the synthesis of dyes, contributing to the development of new colorants.
Used in Antimicrobial Applications:
4-nitro-N-phenyltoluene-2-sulphonamide is used as an active ingredient in some over-the-counter medications due to its antimicrobial properties, helping to combat bacterial infections.
Used in Antiviral Applications:
4-nitro-N-phenyltoluene-2-sulphonamide is used for its antiviral properties, potentially contributing to the development of treatments for viral infections.
Used in Organic Chemistry:
4-nitro-N-phenyltoluene-2-sulphonamide is used as a reagent in various organic chemistry reactions, facilitating the synthesis of other compounds.
Used in Low Toxicity Applications:
4-nitro-N-phenyltoluene-2-sulphonamide is known for its relatively low toxicity, making it suitable for use in applications where reduced toxicity is desired.
Check Digit Verification of cas no
The CAS Registry Mumber 79-88-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 9 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 79-88:
(4*7)+(3*9)+(2*8)+(1*8)=79
79 % 10 = 9
So 79-88-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H12N2O4S/c1-10-7-8-12(15(16)17)9-13(10)20(18,19)14-11-5-3-2-4-6-11/h2-9,14H,1H3
79-88-9Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 67; 68; 183, (2014/05/07)
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
